Theseus Pharmaceuticals IncNASDAQ THRX Stock Report

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-10-07. The firm is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The firm is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The firm's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.